HK1133193A1 - Pharmaceutical compositions comprising nilotinib or its salt - Google Patents

Pharmaceutical compositions comprising nilotinib or its salt

Info

Publication number
HK1133193A1
HK1133193A1 HK09111400.2A HK09111400A HK1133193A1 HK 1133193 A1 HK1133193 A1 HK 1133193A1 HK 09111400 A HK09111400 A HK 09111400A HK 1133193 A1 HK1133193 A1 HK 1133193A1
Authority
HK
Hong Kong
Prior art keywords
nilotinib
salt
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
HK09111400.2A
Other languages
English (en)
Chinese (zh)
Inventor
Nathalie Bruneau
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37684496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1133193(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1133193A1 publication Critical patent/HK1133193A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK09111400.2A 2006-09-27 2009-12-04 Pharmaceutical compositions comprising nilotinib or its salt HK1133193A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06121371A EP1923053A1 (en) 2006-09-27 2006-09-27 Pharmaceutical compositions comprising nilotinib or its salt
PCT/EP2007/060165 WO2008037716A2 (en) 2006-09-27 2007-09-25 Pharmaceutical compositions comprising nilotinib or its salt

Publications (1)

Publication Number Publication Date
HK1133193A1 true HK1133193A1 (en) 2010-03-19

Family

ID=37684496

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09111400.2A HK1133193A1 (en) 2006-09-27 2009-12-04 Pharmaceutical compositions comprising nilotinib or its salt

Country Status (35)

Country Link
US (2) US8293756B2 (pl)
EP (4) EP1923053A1 (pl)
JP (2) JP5567340B2 (pl)
KR (2) KR20090076931A (pl)
CN (2) CN101516344A (pl)
AR (1) AR062980A1 (pl)
AU (1) AU2007301977B2 (pl)
BR (1) BRPI0719438B1 (pl)
CA (1) CA2662571C (pl)
CL (1) CL2007002766A1 (pl)
CO (1) CO6160288A2 (pl)
CY (2) CY1117021T1 (pl)
DK (2) DK2068839T3 (pl)
ES (3) ES2556625T5 (pl)
FI (2) FI2068839T4 (pl)
HK (1) HK1133193A1 (pl)
HR (2) HRP20230753T3 (pl)
HU (2) HUE063083T2 (pl)
IL (1) IL197496A (pl)
JO (1) JO3757B1 (pl)
LT (1) LT3984528T (pl)
MA (1) MA30807B1 (pl)
MX (1) MX2009003184A (pl)
MY (1) MY148237A (pl)
NO (2) NO347404B1 (pl)
NZ (1) NZ575317A (pl)
PE (2) PE20120626A1 (pl)
PL (2) PL3984528T3 (pl)
PT (2) PT2068839E (pl)
RU (1) RU2469707C2 (pl)
SI (2) SI2068839T2 (pl)
TN (1) TN2009000093A1 (pl)
TW (3) TW201418245A (pl)
WO (1) WO2008037716A2 (pl)
ZA (1) ZA200901511B (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
EP2482820A2 (en) 2009-09-28 2012-08-08 Medizinische Universität Wien New use of pdgfrbeta inhibitors
KR20120099650A (ko) * 2009-10-23 2012-09-11 노파르티스 아게 Ｂｃｒ-ａｂｌ, ｃ-ｋｉｔ, ｄｄｒ1, ｄｄｒ2 또는 ｐｄｇｆ-ｒ 키나제 활성에 의해 매개된 증식성 장애 및 다른 병적 상태의 치료 방법
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
IN2011CH01887A (pl) * 2011-06-02 2012-12-14
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
CN102321073A (zh) * 2011-08-12 2012-01-18 西安交通大学 一种尼罗替尼的制备方法
WO2013063000A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
US9301957B2 (en) 2011-11-14 2016-04-05 Novartis Ag Immediate release 4-methyl-3-4[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-YL)-3-(trifluoromethyl)phenyl] benzamide formulation
BR112014011518A2 (pt) * 2011-11-14 2017-05-16 Novartis Ag liberação imediata da formulação 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida
EP2872142A1 (en) 2012-07-11 2015-05-20 Novartis AG Method of treating gastrointestinal stromal tumors
WO2014174496A1 (en) 2013-04-25 2014-10-30 Ranbaxy Laboratories Limited Pharmaceutical gastro-retentive solid oral dosage form of nilotinib
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
ES2908457T3 (es) * 2014-08-11 2022-04-29 Sun Pharmaceutical Ind Ltd Novedosas sales de nilotinib y polimorfos de las mismas
WO2016033304A1 (en) * 2014-08-28 2016-03-03 Codexis, Inc. Imidazoyl anilide derivatives and methods of use
WO2017158625A1 (en) * 2016-03-17 2017-09-21 Sun Pharmaceutical Industries Ltd. Pharmaceutical composition of nilotinib
CN107582531B (zh) * 2016-07-06 2020-12-29 四川科伦药物研究院有限公司 一种利伐沙班固体制剂及其制备方法
CN107320460B (zh) * 2017-08-04 2020-11-03 北京化工大学 一种尼罗替尼口服纳米制剂及其制备方法
CN107441094B (zh) * 2017-08-08 2020-05-22 南方医科大学 尼罗替尼作为治疗登革病毒感染的药物及其制药用途
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
CN116808044A (zh) 2018-06-15 2023-09-29 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
JP2023513045A (ja) 2020-01-31 2023-03-30 ナノコピーア リミテッド ライアビリティ カンパニー 非晶質ニロチニブ微粒子及びその使用
EP4142699A1 (en) 2020-04-30 2023-03-08 Nanocopoeia LLC Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
JP7489849B2 (ja) 2020-07-20 2024-05-24 日本化薬株式会社 ニロチニブ錠剤
CA3224750A1 (en) 2021-06-19 2022-12-22 Helm Ag Granulate composition comprising nilotinib
WO2023285981A1 (en) * 2021-07-15 2023-01-19 Torrent Pharmaceuticals Limited Stable pharmaceutical liquid composition of nilotinib
EP4122452A1 (en) 2021-07-23 2023-01-25 KRKA, d.d., Novo mesto Pharmaceutical composition comprising nilotinib and method of manufacturing the same
EP4260848A1 (en) 2022-04-11 2023-10-18 Lotus Pharmaceutical Co., Ltd. Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072535A (en) * 1970-12-28 1978-02-07 A. E. Staley Manufacturing Company Precompacted-starch binder-disintegrant-filler material for direct compression tablets and dry dosage capsules
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
JP3125221B2 (ja) * 1990-09-01 2001-01-15 大正製薬株式会社 ソファルコン含有固形製剤
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
PT2177517E (pt) 1996-07-24 2011-11-10 Celgene Corp 2-(2,6-dioxopiperidin-3-il)-ftalimida amino-substituída para redução dos níveis de tnf-alfa
TW426516B (en) * 1996-12-06 2001-03-21 Fujisawa Pharmaceutical Co An oral pharmaceutical composition in solid dispersion containing water-insoluble tricyclic compounds
FR2783421B1 (fr) * 1998-09-17 2000-11-24 Cll Pharma Procede de preparation de nouvelles formulations galeniques du fenofibrate, formulations galeniques obtenues par ledit procede et leurs applications
FR2795961B1 (fr) * 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
ES2310166T3 (es) 1999-08-03 2009-01-01 Lilly Icos Llc Composicion farmaceutica que contiene tadalafil.
PL351069A1 (en) * 1999-12-08 2003-03-10 Pharmacia Corp Valdecoxib compositions
MXPA02006660A (es) 2000-01-07 2002-12-13 Transform Pharmaceuticals Inc Formacion, identificacion y analisis de diversas formas solidas de alto rendimiento.
BR0312445A (pt) * 2002-06-07 2005-05-10 Ranbaxy Lab Ltd Sistemas multiunitários para disponibilização de fármaco de liberação modificada
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
US7910030B2 (en) * 2002-11-26 2011-03-22 Universiteit Gent Process and apparatus for continuous wet granulation of powder material
KR20040076203A (ko) * 2003-02-24 2004-08-31 주식회사 엘지생명과학 음식물-약물 상호작용을 방지하기 위한 경구 투여용약제학적 조성물 및 방법
WO2005011635A2 (en) * 2003-08-04 2005-02-10 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
TR200301553A1 (tr) 2003-09-18 2005-10-21 Nobel �La� Sanay�� Ve T�Caret A.�. İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
GB0325031D0 (en) 2003-10-27 2003-12-03 Novartis Ag Organic compounds
WO2005065653A1 (en) * 2003-12-19 2005-07-21 E.I. Du Pont De Nemours And Company Intimate coating of ibuprofen with poloxamers to enhance aqueous dissolution
WO2006013444A1 (en) 2004-07-28 2006-02-09 Ranbaxy Laboratories Limited Preparations of stable pharmaceutical compositions of nateglinide and processes for their preparation
KR20070057901A (ko) * 2004-10-01 2007-06-07 에자이 알앤드디 매니지먼트 가부시키가이샤 미립자 함유 조성물 및 그의 제조 방법
WO2006066932A1 (en) * 2004-12-24 2006-06-29 Lek Pharmaceuticals D.D. Stable pharmaceutical composition comprising an active substance in the form of solid solution
CN101203224B (zh) * 2005-01-28 2010-11-03 诺瓦提斯公司 嘧啶基氨基苯甲酰胺在制备治疗对Tie-2激酶活性的调节有响应的疾病的药物中的用途
AU2006218020A1 (en) * 2005-02-25 2006-08-31 Novartis Ag Pharmaceutical combination of Bcr-Abl and RAF inhibitors
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
GT200600315A (es) * 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
WO2008021347A2 (en) * 2006-08-16 2008-02-21 Novartis Ag Method for making solid dispersions of highly crystalline therapeutic compounds
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt

Also Published As

Publication number Publication date
PL2068839T3 (pl) 2016-06-30
DK3984528T3 (da) 2023-07-31
MY148237A (en) 2013-03-29
NO20220946A1 (no) 2009-04-24
NO20091501L (no) 2009-04-24
ZA200901511B (en) 2010-02-24
ES2556625T3 (es) 2016-01-19
CY1117021T1 (el) 2017-04-05
HUE028204T2 (en) 2016-12-28
PE20120626A1 (es) 2012-06-07
JO3757B1 (ar) 2021-01-31
EP2068839B1 (en) 2015-09-23
CO6160288A2 (es) 2010-05-20
NO346639B1 (no) 2022-11-07
MX2009003184A (es) 2009-04-03
FI3984528T3 (fi) 2023-07-27
HRP20230753T3 (hr) 2023-10-27
BRPI0719438B1 (pt) 2022-04-19
ES2951547T3 (es) 2023-10-23
EP2068839B2 (en) 2022-10-12
HRP20151383T1 (hr) 2016-01-15
TW201418244A (zh) 2014-05-16
WO2008037716A2 (en) 2008-04-03
US8293756B2 (en) 2012-10-23
EP1923053A1 (en) 2008-05-21
KR101598747B1 (ko) 2016-03-02
PL3984528T3 (pl) 2023-08-28
JP2010504942A (ja) 2010-02-18
CL2007002766A1 (es) 2008-08-08
RU2009115782A (ru) 2010-11-10
CN104306350A (zh) 2015-01-28
TWI540128B (zh) 2016-07-01
SI2068839T1 (sl) 2016-02-29
RU2469707C2 (ru) 2012-12-20
BRPI0719438A2 (pt) 2013-12-10
IL197496A (en) 2016-04-21
SI2068839T2 (sl) 2023-01-31
TW200821298A (en) 2008-05-16
TN2009000093A1 (en) 2010-08-19
NO347404B1 (no) 2023-10-16
DK2068839T3 (da) 2016-01-11
AU2007301977A1 (en) 2008-04-03
EP3009128B1 (en) 2023-07-05
CN101516344A (zh) 2009-08-26
JP2014065715A (ja) 2014-04-17
SI3984528T1 (sl) 2023-09-29
US20100087463A1 (en) 2010-04-08
CA2662571A1 (en) 2008-04-03
JP5567340B2 (ja) 2014-08-06
ES2957912T3 (es) 2024-01-29
HRP20151383T4 (hr) 2023-03-03
EP3984528A1 (en) 2022-04-20
FI2068839T4 (fi) 2023-01-31
CY1126116T1 (el) 2023-11-15
EP3984528B1 (en) 2023-07-05
MA30807B1 (fr) 2009-10-01
PT2068839E (pt) 2015-12-30
TWI428333B (zh) 2014-03-01
EP3009128A1 (en) 2016-04-20
PL2068839T5 (pl) 2023-01-30
LT3984528T (lt) 2023-08-10
US8501760B2 (en) 2013-08-06
AR062980A1 (es) 2008-12-17
KR20140121903A (ko) 2014-10-16
ES2556625T5 (es) 2023-03-02
NZ575317A (en) 2011-12-22
WO2008037716A3 (en) 2008-07-17
HUE063083T2 (hu) 2023-12-28
US20130023549A1 (en) 2013-01-24
EP2068839A2 (en) 2009-06-17
PE20081379A1 (es) 2008-11-27
AU2007301977B2 (en) 2011-09-08
KR20090076931A (ko) 2009-07-13
TW201418245A (zh) 2014-05-16
CA2662571C (en) 2016-09-27
IL197496A0 (en) 2009-12-24
PT3984528T (pt) 2023-08-07

Similar Documents

Publication Publication Date Title
FI2068839T4 (fi) Nilotinibia tai sen suolaa käsittäviä farmaseuttisia koostumuksia
EP2001498A4 (en) PHARMACEUTICAL COMPOSITIONS
IL194176A0 (en) Pharmaceutical compositions
GB0625322D0 (en) Pharmaceutical compositions
HK1126667A1 (en) Self preserved aqueous pharmaceutical compositions
HK1138732A1 (en) Pharmaceutical compositions
HK1125295A1 (en) Microtablet-based pharmaceutical preparation
EP2005958A4 (en) TOPICAL PHARMACEUTICAL COMPOSITION
GB0614586D0 (en) Pharmaceutical Formulation
ZA200901702B (en) Self-preserved aqueous pharmaceutical compositions
EP2124959A4 (en) PHARMACEUTICAL COMPOSITION
ZA200901164B (en) Self preserved aqueous pharmaceutical compositions
HU0600939D0 (en) Pharmaceutical compositions
HU0600938D0 (en) Pharmaceutical compositions
GB0609941D0 (en) Pharmaceutical compositions
GB0611079D0 (en) Pharmaceutical compositions
GB0621623D0 (en) Pharmaceutical compositions
GB0622964D0 (en) Pharmaceutical compositions
ZA200808030B (en) Pharmaceutical compositions
GB0617578D0 (en) Pharmaceutical composition
GB0612696D0 (en) Pharmaceutical composition
GB0600032D0 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
AM43 Amendment of standard patent following opposition or revocation proceedings in the designated patent office (acc. sect 43 patent ordinance)